Silencing beta2-adrenergic receptors reduces intraocular pressure: A new approach for glaucoma therapy

Anales de la Real Academia Nacional de Farmacia

Volumn 78, Issue 2, 2012, Pages 230-240

  Pintor, Jesús ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Adrenergic receptors; Glaucoma; Intraocular pressure; SiR

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; EOSIN; HEMATOXYLIN; SMALL INTERFERING RNA;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GLAUCOMA; HISTOPATHOLOGY; INTRAOCULAR PRESSURE; MALE; NONHUMAN; SINGLE BLIND PROCEDURE; STAINING; TISSUE SECTION;

EID: 84882968010     PISSN: None     EISSN: 1697428X     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Sears M., & Mead A. (1983). A major pathway for the regulation of intraocular pressure. Internat Ophthalmol 6, 201-212. (Pubitemid 13003083)
2. Davson H. (1993). The aqueous humour and the intraocular pressure. In: Davson H (ed). Physiology of the eye. Pergamon Press: New York, pp 34-95.
3. Rohde B.H., McLaughlin M.A., & Chiou L.Y. (1985) Existence and role of endogenous ocular melatonin. J Ocul Pharmacol 1, 235-243. (Pubitemid 17187192)
4. Pintor J. (2009) Autonomic Nervous System: Ophthalmic Control. In: Squire LR (ed.) Encyclopedia of Neuroscience. Academic Press: Oxford, pp. 967-974.
5. Behlke M.A. (2006). Progress towards in vivo use of siRNAs. Mol Ther 13, 644-670.
6. .- Bumcrot D., Manoharan M., Koteliansky V., & Sah D.W. (2006). RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol.;2(12),711-719. (Pubitemid 44764213)
7. Reich S.J. (2003). Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol. Vis. 9, 210-216.
8. Tolentino M.J., Brucker A.J., Fosnot J., Ying G.S., Wu I.H., Malik G., Wan S., & Reich S.J. (2004) Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization. Retina 24(1),132-138. (Pubitemid 38240851)
9. Macha S., Mitra A.K., & Hughes, P.M. (2003). Overview of ocular drug delivery. In: Ophthalmic drug delivery systems. Ed. A.K. Mitra. Pp 1-12, Marcel Dekker (USA).
10. Lee, V.H.L. (1990). Mechanism and facilitation of corneal drug penetration. J. Control. Rel. 11, 79-86.
11. Sugrue M.F. (2000). Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. Prog. Ret. Eye Res. 19(1), 87-112.
12. Pfeiffer N. (1997). Dorzolamide: Development and clinical application of a topical carbonic anhydrase inhibitor. Survey Ophthalmol. 42(2), 137-151.
13. Jackson A.L. (2003). Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. 21(6), 635-637.
14. Hornung V. (2005). Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 11(3), 263-70.
15. Fire A. (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 391(6669), 806-811.